



(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4402 (2006.01)
C07D 409/14 (2006.01) A61K 31/4406 (2006.01)
C07D 413/14 (2006.01) A61K 31/4468 (2006.01)
C07D 471/10 (2006.01) A61K 31/5377 (2006.01)
A61K 31/44 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/065289

(22) International Filing Date:

11 December 2015 (11.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/091,221 12 December 2014 (12.12.2014) US
62/238,931 8 October 2015 (08.10.2015) US

(71) Applicant: ACETYLON PHARMACEUTICALS, INC.
[US/US]; 70 Fargo Street, Suite 205, Boston, MA 02210
(US).

(72) Inventors: VAN DUZER, John, H.; 102 Thurlow Street,
Georgetown, MA 01833 (US). MAZITSCHKE, Ralph;
67 Bright Road, Belmont, MA 02478 (US).

(74) Agents: TRINQUE, Brian, C. et al.; Lathrop & Gage,
LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS

(57) Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using
such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.



WO 2016/094824 A1